Avalo Therapeutics Net Worth
Avalo Therapeutics Net Worth Breakdown | AVTX |
Avalo Therapeutics Net Worth Analysis
Avalo Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Avalo Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Avalo Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Avalo Therapeutics' net worth analysis. One common approach is to calculate Avalo Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Avalo Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Avalo Therapeutics' net worth. This approach calculates the present value of Avalo Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Avalo Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Avalo Therapeutics' net worth. This involves comparing Avalo Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Avalo Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Avalo Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avalo Therapeutics' net worth research are outlined below:
| Avalo Therapeutics had very high historical volatility over the last 90 days | |
| Avalo Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Avalo Therapeutics currently holds 17.7 M in liabilities with Debt to Equity (D/E) ratio of 5.62, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Avalo Therapeutics has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Avalo Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 441 K. Net Loss for the year was (35.13 M) with loss before overhead, payroll, taxes, and interest of (9.34 M). | |
| Avalo Therapeutics currently holds about 11.25 M in cash with (49.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2. | |
| Avalo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 73.0% of Avalo Therapeutics shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Avalo Therapeutics, Inc. Short Interest Up 19.2 percent in February |
Avalo Therapeutics Quarterly Good Will |
|
Avalo Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avalo Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avalo Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Avalo Therapeutics Target Price Consensus
Avalo target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Avalo Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Strong Buy |
Most Avalo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Avalo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Avalo Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAvalo Therapeutics Target Price Projection
Avalo Therapeutics' current and average target prices are 8.22 and 37.50, respectively. The current price of Avalo Therapeutics is the price at which Avalo Therapeutics is currently trading. On the other hand, Avalo Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Avalo Therapeutics Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Avalo Therapeutics Target Price
Know Avalo Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avalo Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avalo Therapeutics backward and forwards among themselves. Avalo Therapeutics' institutional investor refers to the entity that pools money to purchase Avalo Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-12-31 | 117.4 K | Velan Capital Investment Management Lp | 2024-12-31 | 110 K | Geode Capital Management, Llc | 2024-12-31 | 104.9 K | Ubs Group Ag | 2024-12-31 | 98.5 K | Allostery Investments Lp | 2024-12-31 | 73.3 K | Sio Capital Management, Llc | 2024-12-31 | 71.5 K | Bank Of Montreal | 2024-12-31 | 60 K | Bmo Capital Markets Corp. | 2024-12-31 | 60 K | Hrt Financial Llc | 2024-12-31 | 40 K | Bvf Inc | 2024-12-31 | 1 M | Ikarian Capital, Llc | 2024-12-31 | 970.3 K |
Follow Avalo Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 83.89 M.Market Cap |
|
Project Avalo Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.26) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.26) | (0.28) |
When accessing Avalo Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Avalo Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avalo Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Avalo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Avalo Therapeutics. Check Avalo Therapeutics' Beneish M Score to see the likelihood of Avalo Therapeutics' management manipulating its earnings.
Evaluate Avalo Therapeutics' management efficiency
Avalo Therapeutics has return on total asset (ROA) of (0.3064) % which means that it has lost $0.3064 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4252) %, meaning that it created substantial loss on money invested by shareholders. Avalo Therapeutics' management efficiency ratios could be used to measure how well Avalo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.26 in 2025. Return On Capital Employed is likely to drop to -0.5 in 2025. At this time, Avalo Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 16.3 M in 2025, despite the fact that Net Tangible Assets are likely to grow to (21.7 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.37 | 15.55 | |
| Tangible Book Value Per Share | 15.07 | 14.32 | |
| Enterprise Value Over EBITDA | 1.08 | 1.14 | |
| Price Book Value Ratio | 0.45 | 0.43 | |
| Enterprise Value Multiple | 1.08 | 1.14 | |
| Price Fair Value | 0.45 | 0.43 | |
| Enterprise Value | -74.2 M | -70.4 M |
Understanding the operational decisions made by Avalo Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 3.1549 | Revenue | Quarterly Revenue Growth 0.055 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avalo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avalo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avalo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avalo Therapeutics Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 30th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 3rd of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Avalo Therapeutics Earnings Estimation Breakdown
The calculation of Avalo Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Avalo Therapeutics is estimated to be 3.23 with the future projection ranging from a low of 3.23 to a high of 3.23. Please be aware that this consensus of annual earnings estimates for Avalo Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
3.23 Lowest | Expected EPS | 3.23 Highest |
Avalo Therapeutics Earnings Projection Consensus
Suppose the current estimates of Avalo Therapeutics' value are higher than the current market price of the Avalo Therapeutics stock. In this case, investors may conclude that Avalo Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Avalo Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 6 | 61.52% | -1.25 | 3.23 | 94.42 |
Avalo Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Avalo Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Avalo Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Avalo Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Avalo Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Avalo Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Avalo Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Avalo Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Avalo Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -1.19 | -1.25 | -0.06 | 5 | ||
2024-08-12 | 2024-06-30 | -6.7 | -14.07 | -7.37 | 110 | ||
2024-05-13 | 2024-03-31 | -1.18 | -141.0 | -139.82 | 11849 | ||
2024-03-28 | 2023-12-31 | -4.8 | -116.21 | -111.41 | 2321 | ||
2023-11-09 | 2023-09-30 | -1.1 | -0.11 | 0.99 | 90 | ||
2023-08-03 | 2023-06-30 | -0.8 | -0.59 | 0.21 | 26 | ||
2023-05-04 | 2023-03-31 | -0.97 | -0.85 | 0.12 | 12 | ||
2023-03-29 | 2022-12-31 | -0.73 | -1.04 | -0.31 | 42 | ||
2022-11-07 | 2022-09-30 | -1.09 | 0.34 | 1.43 | 131 | ||
2022-08-04 | 2022-06-30 | -1.77 | -1.38 | 0.39 | 22 | ||
2022-05-05 | 2022-03-31 | -1.6 | -2.4 | -0.8 | 50 | ||
2022-03-02 | 2021-12-31 | -1.9 | -1.92 | -0.02 | 1 | ||
2021-11-09 | 2021-09-30 | -2.16 | -2.04 | 0.12 | 5 | ||
2021-08-02 | 2021-06-30 | -2.04 | -2.16 | -0.12 | 5 | ||
2021-05-13 | 2021-03-31 | -2.32 | -3.84 | -1.52 | 65 | ||
2021-03-08 | 2020-12-31 | -1.8 | -2.16 | -0.36 | 20 | ||
2020-11-09 | 2020-09-30 | -1.14 | -2.04 | -0.9 | 78 | ||
2020-08-06 | 2020-06-30 | -1.26 | -2.28 | -1.02 | 80 | ||
2020-05-07 | 2020-03-31 | -1.22 | -4.08 | -2.86 | 234 | ||
2020-03-11 | 2019-12-31 | 0.84 | 0.36 | -0.48 | 57 | ||
2019-11-14 | 2019-09-30 | -1.6 | -0.84 | 0.76 | 47 | ||
2019-08-08 | 2019-06-30 | -1.74 | -1.32 | 0.42 | 24 | ||
2019-05-09 | 2019-03-31 | -1.96 | -1.56 | 0.4 | 20 | ||
2019-03-18 | 2018-12-31 | -0.6 | -2.16 | -1.56 | 260 | ||
2018-11-13 | 2018-09-30 | -0.12 | -0.71 | -0.59 | 491 | ||
2018-08-09 | 2018-06-30 | -0.1 | -0.19 | -0.09 | 90 | ||
2018-05-11 | 2018-03-31 | -0.12 | -0.11 | 0.01 | 8 | ||
2017-11-06 | 2017-09-30 | -0.13 | 0.88 | 1.01 | 776 | ||
2017-08-14 | 2017-06-30 | -0.22 | -0.14 | 0.08 | 36 | ||
2017-05-09 | 2017-03-31 | -4.44 | -2.28 | 2.16 | 48 | ||
2017-03-14 | 2016-12-31 | -8.04 | -2.16 | 5.88 | 73 | ||
2016-11-08 | 2016-09-30 | -6.12 | -8.4 | -2.28 | 37 | ||
2016-08-15 | 2016-06-30 | -5.34 | -4.92 | 0.42 | 7 | ||
2016-05-16 | 2016-03-31 | -3.96 | -7.08 | -3.12 | 78 | ||
2016-03-23 | 2015-12-31 | -3.36 | -6.36 | -3.0 | 89 |
Avalo Therapeutics Corporate Management
| Blake MD | Scientific Advisor | Profile | |
| Barbara Slusher | Founder Board | Profile | |
| Maxim CFA | VP Relations | Profile | |
| Stephen Thomas | VP Discovery | Profile | |
| Christopher Sullivan | Chief Officer | Profile |
Already Invested in Avalo Therapeutics?
The danger of trading Avalo Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avalo Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avalo Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avalo Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.